Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19

• DOI: 10.1038/s41467-022-33801-z
• Publication Date: 2022-10-12T18:02:47Z
• Authors: Nicolas de Prost; Etienne Audureau; Nicholas Heming; Elyanne Gault; Tài Pham; Amal Chaghouri; Nina de Montmollin; Guillaume Voiriot; Laurence Morand-J...; Adrien Joseph; Marie-Laure Chaix; Sébastien Préau; Raphaël Favory; Aurélie Guigon; Charles-Edouard Luyt; Sonia Burrel; Julien Mayaux; Stéphane Marot; Damien Roux; Diane Descamps; Sylvie Meireles; Frédéric Pène; Flore Rozenberg; Damien Contou; Amandine Henry; Stéphane Gaudry; Ségolène Brichler; Jean-François Timsit; Antoine Kimmoun; Cédric Hartard; Louise-Marie Jand...; Samira Fafi-Kremer; Paul Gabarre; Malo Emery; Claudio Garcia-Sa...; Sébastien Jochmans; Aurélia Pitsch; Djillali Annane; Elie Azoulay; Armand Mekontso D...; Christophe Rodriguez; Jean-Michel Pawlo...; Slim Fourati
• Keywords: 2019-20 coronavirus outbreak; Sars virus; Betacoronavirus

Abstract Infection with SARS-CoV-2 variant Omicron is considered to be less severe than infection Delta, rarer occurrence of disease requiring intensive care. Little information available on comorbid factors, clinical conditions and specific viral mutational patterns associated the severity infection. In this multicenter prospective cohort study, patients consecutively admitted for COVID-19 in 20 care units France between December 7th 2021 May 1st 2022 were included. Among 259 patients, we show that phenotype infected ( n = 148) different from those Delta 111). We observe no significant relationship lineages/sublineages 28-day mortality (adjusted odds ratio [95% confidence interval] 0.68 [0.35–1.32]; p 0.253). Omicron-infected 43.2% are immunocompromised, most whom have received two doses vaccine or more (85.9%) but display a poor humoral response vaccination. The rate immunocompromised significantly higher non-immunocompromised (46.9% vs 26.2%; 0.009). Omicron, there association sublineages (BA.1/BA.1.1 109) BA.2 21)) any genome polymorphisms/mutational profile mortality.